pimecrolimus pimecrolimus pimecrolimus is an immunomodulating agent of the calcineurin inhibitor class used in the treatment of atopic dermatitis (eczema). it is available as a topical cream, once marketed by novartis (however, galderma has been promoting the compound in canada since early 2007) under the trade name elidel. pimecrolimusclinical datatrade nameselidelahfs/drugs.commonographpregnancycategory au: b3 routes ofadministrationtopicalatc coded11ah02 (who) legal statuslegal status us: ℞-only pharmacokinetic databioavailabilitylow systemic absorptionprotein binding74%–87%metabolismhepatic cyp3aidentifiers iupac name (3s,4r,5s,8r,9e,12s,14s,15r,16s,18r,19r,26as)-3--8-ethyl-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-14,16-dimethoxy-4,10,12,18-tetramethyl-15,19-epoxy-3h-pyridooxaazacyclotricosin-1,7,20,21(4h,23h)-tetrone cas number137071-32-0 ypubchem cid16051947drugbankdb00337 ychemspider10482089 yunii7kyv510875chemblchembl1200686 ncomptox dashboard (epa)dtxsid2046674 echa infocard100.124.895 chemical and physical dataformulac43h68clno11molar mass810.46 g·mol−13d model (jsmol)interactive image smiles cl1cc(c1oc)\c=c(/c)2oc(=o)4ccccn4c(=o)c(=o)3(o)o((c(c)cc(\c)=c\(cc)c(=o)c(o)2c)oc)(oc)c3c inchi inchi=1s/c43h68clno11/c1-10-30-18-24(2)17-25(3)19-36(53-8)39-37(54-9)21-27(5)43(51,56-39)40(48)41(49)45-16-12-11-13-32(45)42(50)55-38(28(6)33(46)23-34(30)47)26(4)20-29-14-15-31(44)35(22-29)52-7/h18,20,25,27-33,35-39,46,51h,10-17,19,21-23h2,1-9h3/b24-18+,26-20+/t25-,27+,28+,29-,30+,31+,32-,33-,35+,36-,37-,38+,39+,43+/m0/s1 ykey:kasdhrxlyqoakz-zpsxytitsa-n y ny (what is this?) (verify) medical uses it has been proven to be effective in various inflammatory skin diseases, e.g., seborrheic dermatitis, cutaneous lupus erythematosus, oral lichen planus, vitiligo, and psoriasis. tacrolimus and pimecrolimus are both calcineurin inhibitors and function as immunosuppressants. atopic dermatitis if topical corticosteroids and moisturisers fail in the treatment of atopic dermatitis, short-term treatment with topical calcineurin inhibitors such as tacrolimus or pimecrolimus may be tried. both tacrolimus and pimecrolimus are effective and safe to use in ad. side effects